Pennant International broker maintains 95% share price upside on £3.8m contract wins

Pennant International Group plc
[shareaholic app="share_buttons" id_name="post_below_content"]

Pennant International (LON:PEN), a leading provider of training systems and support for defence equipment maintenance, has announced two new contract wins worth approximately £3.8 million. These deals mark a significant step in the company’s ongoing efforts to convert its robust £10 million+ sales pipeline, as outlined in September’s interim results.

The most substantial of the two contracts comes under Pennant’s long-term agreement with BAE Systems Australia. Valued at £3.6 million, the contract will deliver five upgraded training systems, which are advanced versions of Pennant’s existing Integrated Avionics Maintenance Trainers. These systems will enhance the maintenance training capability for defence clients and are expected to be delivered over a 2.5-year period. Crucially, the milestone-based payment terms are designed to be working capital neutral, helping Pennant manage cash flow effectively.

In addition, Pennant has secured a new customer – a European aircraft equipment original equipment manufacturer (OEM) – for an interactive 3D training package. The initial phase of this contract is valued at £150,000 and is expected to be completed within six months. Further phases could take the total value of the contract to £800,000, highlighting a promising new revenue stream.

These contract wins align well with Pennant’s strategic focus on high-margin upgrades and virtual training solutions, and they demonstrate the company’s ability to win repeat business while also bringing new customers on board.

Andrew Renton, Director of Research at Cavendish, highlighted the significance of these developments, stating:
“These wins demonstrate solid progress in converting the identified pipeline and validate Pennant’s capability to secure both repeat business from existing clients and establishing new customer relationships.”

Renton also noted that these developments bolster confidence in the firm’s unchanged forecasts. Pennant continues to trade at a discount relative to its peers, with a FY26E EV/adj EBITDA multiple of 6.4x, compared to 8.6x for the UK small-cap data and productivity software peer group.

Key Financial Highlights (as of FY2024 and Estimates)

  • FY2024 Revenue: £13.8m
  • FY2025 Revenue Estimate: £10.0m
  • FY2026 Revenue Estimate: £13.0m
  • FY2024 Adj. EBITDA: £1.7m
  • FY2026 Adj. EBITDA Estimate: £1.6m
  • Target Share Price: 40.0p (current: 20.5p, implying 95% upside)

Despite a challenging year forecast for 2025, these new contracts suggest a rebound in growth is on the horizon, with projected revenue growth of 30% in 2026 and a return to EBITDA profitability.

On a Final Note

Pennant’s recent contract wins with both an established defence partner and a new European OEM client reflect strong strategic execution and a solidifying reputation in virtual training systems. With growth potential reaffirmed and valuation remaining attractive, Cavendish maintains its bullish stance, forecasting significant upside for investors who back Pennant’s vision.

Share on:
Find more news, interviews, share price & company profile here for:

    Penumbra, Inc. (PEN) Stock Analysis: Unlocking a 20% Upside Potential in the Booming Medical Devices Market

    Penumbra, Inc. (PEN), a key player in the healthcare sector specializing in medical devices, is currently capturing the attention of investors due to its promising growth potential and innovative product

    Penumbra, Inc. (PEN) Stock Analysis: A Look at Its 22.30% Potential Upside and Robust Growth Prospects

    In the ever-evolving landscape of healthcare innovation, Penumbra, Inc. (NYSE: PEN) stands out as a formidable player. Specializing in medical devices, the company is renowned for its cutting-edge solutions in

    Penumbra, Inc. (PEN) Stock Analysis: Healthcare Innovator with a 16.60% Potential Upside

    Penumbra, Inc. (NYSE: PEN), a frontrunner in the medical devices industry, continues to capture the attention of investors with its robust growth potential and pioneering technological advancements. At a current

    Penumbra, Inc. (PEN) Stock Analysis: Exploring a 18.46% Potential Upside in the Medical Devices Sector

    Penumbra, Inc. (NYSE: PEN), a prominent player in the healthcare sector, specifically within the medical devices industry, has been capturing the attention of investors with its innovative product offerings and

    Penumbra, Inc. (PEN) Stock Analysis: Exploring a 19.72% Potential Upside in the Medical Devices Sector

    Penumbra, Inc. (NYSE: PEN) continues to capture investor attention with its significant growth prospects in the healthcare sector, particularly within the medical devices industry. With a market capitalization of $9.88

    Penumbra, Inc. (PEN) Stock Analysis: Exploring a Robust 19.72% Potential Upside

    Investors looking into the healthcare sector should pay close attention to Penumbra, Inc. (NYSE: PEN), a prominent player in the medical devices industry. With a market capitalization of $9.88 billion,

    Search

    Search